Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Prostate Cancer: Quo Vadis?

Logothetis CJ, Aparicio A, Koinis F, Corn PG, Efstathiou E.

Eur Urol. 2019 Jul 9. pii: S0302-2838(19)30521-4. doi: 10.1016/j.eururo.2019.06.031. [Epub ahead of print]

PMID:
31300238
2.

Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.

Tannir NM, Msaouel P, Ross JA, Devine CE, Chandramohan A, Gonzalez GMN, Wang X, Wang J, Corn PG, Lim ZD, Pruitt L, Karam JA, Wood CG, Zurita AJ.

Eur Urol Oncol. 2019 Jul 1. pii: S2588-9311(19)30079-3. doi: 10.1016/j.euo.2019.06.004. [Epub ahead of print]

PMID:
31272939
3.

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.

Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM.

Eur J Cancer. 2019 Jun;114:67-75. doi: 10.1016/j.ejca.2019.04.003. Epub 2019 May 7.

PMID:
31075726
4.

Taxane-based Combination Therapies for Metastatic Prostate Cancer.

Corn PG, Agarwal N, Araujo JC, Sonpavde G.

Eur Urol Focus. 2019 May;5(3):369-380. doi: 10.1016/j.euf.2017.11.009. Epub 2017 Dec 21. Review.

PMID:
29275145
5.

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.

Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, Knudsen KE, Stadler WM, Feng FY, Chinnaiyan AM.

J Clin Oncol. 2018 Apr 1;36(10):991-999. doi: 10.1200/JCO.2017.75.7310. Epub 2017 Dec 20. Erratum in: J Clin Oncol. 2018 May 20;36(15):1541.

6.

Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.

Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC.

Clin Cancer Res. 2018 Feb 1;24(3):696-707. doi: 10.1158/1078-0432.CCR-17-1872. Epub 2017 Nov 14.

7.

Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy.

Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM.

Cancer Chemother Pharmacol. 2017 Sep;80(3):583-589. doi: 10.1007/s00280-017-3391-9. Epub 2017 Jul 20.

PMID:
28730293
8.

Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.

Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC.

Sci Signal. 2017 May 23;10(480). pii: eaam7479. doi: 10.1126/scisignal.aam7479.

9.

Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.

Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, Zuo X, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick GE, Troncoso P, Corn PG, Navone N, Zhang W, Li S, Thompson TC.

Cell Rep. 2017 Feb 21;18(8):1970-1981. doi: 10.1016/j.celrep.2017.01.072.

10.

Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.

Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Lin SH, Satcher RL, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E.

Clin Genitourin Cancer. 2017 Jun;15(3):363-370. doi: 10.1016/j.clgc.2017.01.010. Epub 2017 Jan 18.

PMID:
28216278
11.

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.

Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN Jr, Tannir NM.

Ann Oncol. 2017 Apr 1;28(4):804-808. doi: 10.1093/annonc/mdw676.

12.

Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin.

Bilen MA, Cauley DH, Atkinson BJ, Chen HC, Kaya DH, Wang X, Vikram R, Tu SM, Corn PG, Kim J.

Clin Genitourin Cancer. 2017 Jun;15(3):e429-e435. doi: 10.1016/j.clgc.2016.12.003. Epub 2016 Dec 13.

13.

Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.

Basourakos SP, Li L, Aparicio AM, Corn PG, Kim J, Thompson TC.

Curr Med Chem. 2017;24(15):1586-1606. doi: 10.2174/0929867323666161214114948. Review.

14.

Paired High-Content Analysis of Prostate Cancer Cells in Bone Marrow and Blood Characterizes Increased Androgen Receptor Expression in Tumor Cell Clusters.

Carlsson A, Kuhn P, Luttgen MS, Dizon KK, Troncoso P, Corn PG, Kolatkar A, Hicks JB, Logothetis CJ, Zurita AJ.

Clin Cancer Res. 2017 Apr 1;23(7):1722-1732. doi: 10.1158/1078-0432.CCR-16-1355. Epub 2016 Oct 4.

15.

The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study.

Dayyani F, Zurita AJ, Nogueras-González GM, Slack R, Millikan RE, Araujo JC, Gallick GE, Logothetis CJ, Corn PG.

BMC Cancer. 2016 Sep 6;16:721. doi: 10.1186/s12885-016-2723-1.

16.

Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer.

Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Park S, Ren C, Li L, Basourakos SP, Hoang A, Efstathiou E, Wang X, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC.

Oncotarget. 2016 Jul 19;7(29):46321-46334. doi: 10.18632/oncotarget.10113.

17.

CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment.

Zhang T, Tseng C, Zhang Y, Sirin O, Corn PG, Li-Ning-Tapia EM, Troncoso P, Davis J, Pettaway C, Ward J, Frazier ML, Logothetis C, Kolonin MG.

Nat Commun. 2016 May 31;7:11674. doi: 10.1038/ncomms11674.

18.

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ; Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol. 2016 Apr 20;34(12):1402-18. doi: 10.1200/JCO.2015.64.2702. Epub 2016 Feb 22.

19.

Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates.

Maiti A, Brown RE, Corn PG, Murthy R, Ganeshan DM, Tsimberidou AM, Subbiah V.

Clin Genitourin Cancer. 2016 Apr;14(2):e187-93. doi: 10.1016/j.clgc.2015.11.004. Epub 2015 Nov 11. No abstract available.

20.

Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.

Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE.

Clin Cancer Res. 2016 Jan 1;22(1):107-21. doi: 10.1158/1078-0432.CCR-15-0235. Epub 2015 Aug 13.

21.

Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases.

Kalra S, Atkinson BJ, Matrana MR, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E.

BJU Int. 2016 May;117(5):761-5. doi: 10.1111/bju.13185. Epub 2015 Jul 6.

22.

Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.

Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen SJ, Siefker-Radtke AO, Aparicio A, Corn PG, Tannir NM.

Clin Genitourin Cancer. 2015 Jun;13(3):218-24. doi: 10.1016/j.clgc.2014.10.004. Epub 2014 Oct 24.

23.

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, Elfiky A, Scheffold C, Laird AD, Schimmoller F, Basch EM, Scher HI.

J Clin Oncol. 2014 Oct 20;32(30):3391-9. doi: 10.1200/JCO.2013.54.5954. Epub 2014 Sep 15.

24.

Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.

Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Li Ning Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM.

Sci Transl Med. 2014 Sep 3;6(252):252ra122. doi: 10.1126/scitranslmed.3009332. Erratum in: Sci Transl Med. 2015 May 13;7(287):287er3. Tapia, Elsa M Li-Ning [corrected to Li Ning Tapia, Elsa M].

25.

Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer.

Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM.

Cancer. 2015 Jan 1;121(1):69-76. doi: 10.1002/cncr.28971. Epub 2014 Aug 22.

26.

DNA damage response and prostate cancer: defects, regulation and therapeutic implications.

Karanika S, Karantanos T, Li L, Corn PG, Thompson TC.

Oncogene. 2015 May 28;34(22):2815-22. doi: 10.1038/onc.2014.238. Epub 2014 Aug 18. Review.

27.

Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.

Hussain M, Corn PG, Michaelson MD, Hammers HJ, Alumkal JJ, Ryan CJ, Bruce JY, Moran S, Lee SY, Lin HM, George DJ; Prostate Cancer Clinical Trials Consortium, a program of the Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation.

Clin Cancer Res. 2014 Aug 15;20(16):4218-27. doi: 10.1158/1078-0432.CCR-14-0356. Epub 2014 Jun 25.

28.

Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.

Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC.

Sci Signal. 2014 May 20;7(326):ra47. doi: 10.1126/scisignal.2005070.

29.

Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.

Basch E, Autio KA, Smith MR, Bennett AV, Weitzman AL, Scheffold C, Sweeney C, Rathkopf DE, Smith DC, George DJ, Higano CS, Harzstark AL, Sartor AO, Gordon MS, Vogelzang NJ, de Bono JS, Haas NB, Corn PG, Schimmoller F, Scher HI.

Eur Urol. 2015 Feb;67(2):310-8. doi: 10.1016/j.eururo.2014.02.013. Epub 2014 Feb 20.

PMID:
24631409
30.

Src signaling pathways in prostate cancer.

Varkaris A, Katsiampoura AD, Araujo JC, Gallick GE, Corn PG.

Cancer Metastasis Rev. 2014 Sep;33(2-3):595-606. doi: 10.1007/s10555-013-9481-1. Review.

31.

Targeting fibroblast growth factor pathways in prostate cancer.

Corn PG, Wang F, McKeehan WL, Navone N.

Clin Cancer Res. 2013 Nov 1;19(21):5856-66. doi: 10.1158/1078-0432.CCR-13-1550. Epub 2013 Sep 19. Review.

32.

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.

Karantanos T, Corn PG, Thompson TC.

Oncogene. 2013 Dec 5;32(49):5501-11. doi: 10.1038/onc.2013.206. Epub 2013 Jun 10. Review.

33.

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ.

Clin Cancer Res. 2013 Jul 1;19(13):3621-30. doi: 10.1158/1078-0432.CCR-12-3791. Epub 2013 May 6.

34.

Optimal therapy sequencing in metastatic castration-resistant prostate cancer.

Abouharb S, Corn PG.

Curr Oncol Rep. 2013 Jun;15(3):217-23. doi: 10.1007/s11912-013-0311-y. Review.

PMID:
23568599
35.

Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study.

Corn PG, Song DY, Heath E, Maier J, Meyn R, Kuban D, DePetrillo TA, Mathew P.

Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):540-5. doi: 10.1016/j.ijrobp.2012.12.029. Epub 2013 Mar 28.

36.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M.

J Clin Oncol. 2013 Feb 1;31(4):412-9. doi: 10.1200/JCO.2012.45.0494. Epub 2012 Nov 19.

37.

PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era.

McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e39-46. doi: 10.1016/j.ijrobp.2012.08.036. Epub 2012 Oct 23.

38.

Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials.

Som A, Tu SM, Liu J, Wang X, Qiao W, Logothetis C, Corn PG.

Br J Cancer. 2012 Oct 23;107(9):1547-53. doi: 10.1038/bjc.2012.436. Epub 2012 Oct 2.

39.

The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development.

Corn PG.

Cancer Manag Res. 2012;4:183-93. doi: 10.2147/CMAR.S32839. Epub 2012 Jul 25.

40.

Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Gallick GE, Corn PG, Zurita AJ, Lin SH.

Future Med Chem. 2012 Jan;4(1):107-19. doi: 10.4155/fmc.11.161.

41.

The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials.

Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE.

Expert Opin Investig Drugs. 2011 Dec;20(12):1677-84. doi: 10.1517/13543784.2011.631523. Epub 2011 Oct 28. Review.

42.

Novel therapies for metastatic castrate-resistant prostate cancer.

Dayyani F, Gallick GE, Logothetis CJ, Corn PG.

J Natl Cancer Inst. 2011 Nov 16;103(22):1665-75. doi: 10.1093/jnci/djr362. Epub 2011 Sep 13. Review.

43.

Using methylation analysis to assess tumor heterogeneity in familial breast cancer.

Corn PG.

Cancer Biol Ther. 2011 Jun 15;11(12):1065-6. Epub 2011 Jun 15. No abstract available.

PMID:
21577053
44.
45.

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy.

Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM.

Ann Oncol. 2011 May;22(5):1048-53. doi: 10.1093/annonc/mdq563. Epub 2010 Nov 29.

46.

MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal cancer cell lines.

Tsao CC, Corn PG.

Cancer Biol Ther. 2010 Dec 15;10(12):1315-25. Epub 2010 Dec 15.

PMID:
20953142
47.

Methylation marks the path for biomarker development in breast cancer research.

Corn PG.

Cancer Biol Ther. 2009 Dec;8(23):2260-2. Epub 2009 Dec 25. No abstract available.

PMID:
19901521
48.

Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.

Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N.

J Clin Oncol. 2009 Sep 1;27(25):4076-81. doi: 10.1200/JCO.2008.21.3660. Epub 2009 Jul 27.

49.

Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity.

Pataer A, Swisher SG, Roth JA, Logothetis CJ, Corn PG.

Cancer Biol Ther. 2009 Feb;8(3):245-52. Epub 2009 Feb 8.

50.

Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis.

Tsao CC, Teh BT, Jonasch E, Shreiber-Agus N, Efstathiou E, Hoang A, Czerniak B, Logothetis C, Corn PG.

Cancer Biol Ther. 2008 Oct;7(10):1619-27. Epub 2008 Oct 3.

PMID:
19018165

Supplemental Content

Support Center